Palisade Bio Announces Cancellation of Special Meeting of Stockholders

Core Viewpoint - Palisade Bio, Inc. has decided to cancel its special meeting of stockholders originally scheduled for October 10, 2025, due to the lack of a required quorum [1][2]. Group 1: Special Meeting Details - The special meeting was previously adjourned to September 26, 2025, but was adjourned again without any business being conducted due to insufficient proxies to form a quorum [2]. - The company has not received the necessary proxies to constitute a quorum and has withdrawn the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025 [2]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [3]. - The company aims to transform the treatment landscape through a targeted approach with its novel therapeutics [3].